Skip to main content

Edgewise Therapeutics, Inc.

EWTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001710072

In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Edgewise Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
6 filings
5 insiders, $9.78M in total
Insiders trading
5
Net value
−$9.78M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Edgewise Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Edgewise Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Nofi MichaelChief Financial Officer–Aug 17, 20262
Donovan Joanne M.CMO8,625Aug 17, 20265
Russell Alan JChief Scientific Officer31,466Aug 17, 20263
Moore John RGeneral Counsel17,697Aug 17, 20261
Derakhshan BehradChief Business Officer31,826Aug 17, 20261
Koch KevinPresident and CEO52,488Aug 14, 20261
Root Jonathan DDirector0IndirectJul 17, 20261
Fox Jonathan CDirector24,833Jul 1, 20266
Thompson Peter A.Director, 10% Owner443,792IndirectJun 17, 20261
Morris ArleneDirector–Jun 17, 20261
Brege LauraDirector–Jun 17, 20261
Edris BadreddinDirector19,820Jun 16, 20262
Martin Christopher NathanDirector–Jun 16, 20262
Carruthers R MichaelChief Financial Officer86,162Aug 14, 20250
Blaustein RobertChief Development Officer–Aug 14, 20250
OrbiMed Advisors LLCDirector, 10% Owner443,792IndirectApr 4, 20250
OrbiMed Capital GP VI LLCDirector, 10% Owner443,792IndirectApr 4, 20250
OrbiMed Genesis GP LLCDirector, 10% Owner443,792IndirectApr 4, 20250
Semigran MarcChief Development Officer6,716Dec 27, 20240
Novo Holdings A/S10% Owner6,071,703Sep 16, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 27, 2021 (view filing)Sep 23-274 daysRussell Alan JChief Scientific OfficerSSale−58.5K$18.30−$1.07M−22.2%205.6K after5 lots
Sep 30, 2021 (view filing)Sep 28-292 daysRussell Alan JChief Scientific OfficerSSale−26.5K$17.10−$452.5K−12.9%179.1K after3 lots
Oct 5, 2021 (view filing)Oct 1-54 daysRussell Alan JChief Scientific OfficerSSale−5.78K$18.24−$105.4K−3.2%173.3K after3 lots
Oct 8, 2021 (view filing)Oct 6-82 daysRussell Alan JChief Scientific OfficerSSale−21.0K$18.39−$386.7K−12.1%152.3K after3 lots
Oct 13, 2021 (view filing)Oct 112 daysRussell Alan JChief Scientific OfficerSSale−1.27K$18.02−$22.9K−0.8%151.0K after
Oct 18, 2021 (view filing)Oct 14-154 daysRussell Alan JChief Scientific OfficerSSale−7.18K$18.17−$130.5K−4.8%143.8K after3 lots
Nov 3, 2021 (view filing)Nov 1-32 daysRussell Alan JChief Scientific OfficerSSale−44.2K$17.88−$789.9K−30.7%99.7K after5 lots
Nov 8, 2021 (view filing)Nov 4-84 daysRussell Alan JChief Scientific OfficerSSale−29.5K$19.82−$583.7K−29.5%70.2K after4 lots
Nov 12, 2021 (view filing)Nov 9-123 daysRussell Alan JChief Scientific OfficerSSale−69.7K$19.91−$1.39M−99.3%479 after7 lots
Nov 17, 2021 (view filing)Nov 152 daysRussell Alan JChief Scientific OfficerSSale−479$19.11−$9.16K−100.0%0 after2 lots
May 18, 2022 (view filing)May 162 daysMoore John RGeneral CounselSSale−10.8K$7.42−$80.1K−78.3%3.00K after
May 20, 2022 (view filing)May 182 daysThompson Peter A.Director, 10% OwnerPPurchase+138.0K$7.21+$995.0K+1.0%13.5M after
May 20, 2022 (view filing)4:38 PM ETMay 182 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+138.0K$7.21+$995.0K+1.0%13.5M afterDuplicate filing
Jun 7, 2022 (view filing)Jun 3-74 daysMoore John RGeneral CounselSSale−47.3K$6.26−$296.0K−94.0%3.00K after4 lots
Jun 10, 2022 (view filing)Jun 8-102 daysMoore John RGeneral CounselSSale−27.3K$6.44−$175.8K−90.1%3.00K after3 lots
Jun 15, 2022 (view filing)Jun 13-152 daysMoore John RGeneral CounselSSale−26.4K$6.08−$160.5K−89.8%3.00K after4 lots
Jun 21, 2022 (view filing)Jun 16-215 daysMoore John RGeneral CounselSSale−67.9K$6.83−$463.9K−95.8%3.00K after3 lots
Jul 7, 2022 (view filing)Jul 5-62 daysMoore John RGeneral CounselSSale−9.23K$8.37−$77.3K−75.5%3.00K after2 lots
Aug 5, 2022 (view filing)Aug 32 daysMoore John RGeneral CounselSSale−9.23K$9.31−$85.9K−75.5%3.00K after
Sep 8, 2022 (view filing)Sep 62 daysMoore John RGeneral CounselSSale−4.73K$10.91−$51.6K−61.2%3.00K after2 lots
Sep 16, 2022 (view filing)Sep 16Same dayThompson Peter A.Director, 10% OwnerPPurchase+484.5K$10.32+$5.00M+3.6%14.0M after
Sep 16, 2022 (view filing)Sep 142 daysNovo Holdings A/S10% OwnerPPurchase+484.5K$10.32+$5.00M+8.7%6.07M after
Sep 16, 2022 (view filing)4:31 PM ETSep 16Same dayOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+484.5K$10.32+$5.00M+3.6%14.0M afterDuplicate filing
Oct 5, 2022 (view filing)Oct 32 daysMoore John RGeneral CounselSSale−4.73K$9.76−$46.2K−61.2%3.00K after
May 3, 2023 (view filing)May 21 dayKoch KevinPresident and CEOSSale−3.20K$8.90−$28.5K−30.8%7.21K after
May 3, 2023 (view filing)May 21 dayDonovan Joanne M.CMOSSale−3.25K$8.90−$29.0K−24.6%9.96K after
May 3, 2023 (view filing)May 21 dayRussell Alan JChief Scientific OfficerSSale−1.60K$8.90−$14.3K−0.9%176.2K after
May 3, 2023 (view filing)May 21 dayCarruthers R MichaelChief Financial OfficerSSale−1.34K$8.90−$11.9K−7.7%16.1K after
May 3, 2023 (view filing)May 21 dayMoore John RGeneral CounselSSale−1.90K$8.90−$16.9K−22.4%6.57K after
May 3, 2023 (view filing)May 21 dayDerakhshan BehradChief Business OfficerSSale−1.75K$8.90−$15.5K−19.9%7.02K after
Dec 28, 2023 (view filing)Dec 262 daysRussell Alan JChief Scientific OfficerSSale−172.6K$9.33−$1.61M−98.0%3.61K after
Dec 28, 2023 (view filing)Dec 271 dayMoore John RGeneral CounselSSale−8.50K$10.50−$89.2K−100.0%0 after
Dec 28, 2023 (view filing)Dec 262 daysFox Jonathan CDirectorPPurchase+10.9K$9.30+$101.0KNew position10.9K after
Jan 25, 2024 (view filing)Jan 232 daysThompson Peter A.Director, 10% OwnerPPurchase+454.5K$11.00+$5.00M+3.3%14.4M after
Jan 25, 2024 (view filing)Jan 232 daysCarruthers R MichaelChief Financial OfficerSSale−90.0K$15.78−$1.42M−75.6%29.0K after10b5-1
Jan 25, 2024 (view filing)4:28 PM ETJan 232 daysOrbiMed Advisors LLC and 2 othersDirector, 10% OwnerPPurchase+454.5K$11.00+$5.00M+3.3%14.4M afterDuplicate filing
Feb 9, 2024 (view filing)Feb 7-92 daysDerakhshan BehradChief Business OfficerSSale−10.0K$20.02−$200.2K−58.8%7.02K after3 lots10b5-1
Feb 9, 2024 (view filing)Feb 7-92 daysMoore John RGeneral CounselSSale−29.8K$20.00−$596.8K−100.0%0 after3 lots10b5-1
May 3, 2024 (view filing)May 21 dayKoch KevinPresident and CEOSSale−3.15K$18.91−$59.6K−17.9%14.5K after
May 3, 2024 (view filing)May 21 dayDonovan Joanne M.CMOSSale−3.68K$18.91−$69.6K−15.6%19.9K after
May 3, 2024 (view filing)May 21 dayRussell Alan JChief Scientific OfficerSSale−1.58K$18.91−$29.8K−17.9%7.24K after
May 3, 2024 (view filing)May 21 dayDerakhshan BehradChief Business OfficerSSale−1.72K$18.91−$32.5K−11.3%13.4K after
May 3, 2024 (view filing)May 21 dayCarruthers R MichaelChief Financial OfficerSSale−2.16K$18.91−$40.8K−5.8%35.2K after
May 3, 2024 (view filing)May 21 dayMoore John RGeneral CounselSSale−1.96K$18.91−$37.0K−37.6%3.25K after
Sep 24, 2024 (view filing)Sep 204 daysCarruthers R MichaelChief Financial OfficerSSale−125.1K$28.57−$3.57M−94.8%6.90K after4 lots
Sep 24, 2024 (view filing)Sep 204 daysDerakhshan BehradChief Business OfficerSSale−42.1K$29.03−$1.22M−73.6%15.1K after
Sep 24, 2024 (view filing)Sep 204 daysDonovan Joanne M.CMOSSale−7.16K$28.29−$202.6K−33.0%14.5K after
Sep 24, 2024 (view filing)Sep 20-234 daysMoore John RGeneral CounselSSale−70.9K$28.15−$2.00M−95.6%3.25K after2 lots
Sep 24, 2024 (view filing)8:25 PM ETSep 204 daysRussell Alan JChief Scientific OfficerSSale−75.0K$28.27−$2.12M−85.5%12.7K after2 lots
Dec 27, 2024 (view filing)Dec 243 daysSemigran MarcChief Development OfficerSSale−29.7K$29.68−$881.9K−81.6%6.72K after2 lots10b5-1